Baader Bank Aktiengesellschaft Invests $478,000 in Natera, Inc. (NASDAQ:NTRA)

Baader Bank Aktiengesellschaft purchased a new stake in Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,414 shares of the medical research company’s stock, valued at approximately $478,000.

Several other institutional investors have also made changes to their positions in NTRA. Norges Bank bought a new stake in shares of Natera in the fourth quarter valued at approximately $83,970,000. Perceptive Advisors LLC boosted its stake in shares of Natera by 289.7% in the fourth quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock valued at $53,258,000 after buying an additional 632,047 shares during the period. Vanguard Group Inc. boosted its stake in shares of Natera by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after buying an additional 588,147 shares during the period. First Light Asset Management LLC boosted its stake in shares of Natera by 295.9% in the first quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock valued at $60,063,000 after buying an additional 490,822 shares during the period. Finally, Farallon Capital Management LLC raised its position in Natera by 13.0% during the first quarter. Farallon Capital Management LLC now owns 3,927,683 shares of the medical research company’s stock valued at $359,226,000 after purchasing an additional 452,800 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Trading Up 3.2 %

NASDAQ NTRA traded up $3.75 on Thursday, reaching $122.25. The company had a trading volume of 1,251,752 shares, compared to its average volume of 1,400,707. The firm has a market cap of $15.01 billion, a price-to-earnings ratio of -38.86 and a beta of 1.48. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $122.48. The business has a 50 day moving average of $108.46 and a two-hundred day moving average of $96.27. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.12 and a quick ratio of 3.98.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The business had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same period in the prior year, the business posted ($0.97) earnings per share. Natera’s quarterly revenue was up 58.1% on a year-over-year basis. Analysts forecast that Natera, Inc. will post -2.43 EPS for the current year.

Insiders Place Their Bets

In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $108,627.89. Following the completion of the sale, the insider now directly owns 206,400 shares in the company, valued at approximately $21,211,728. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $108,627.89. Following the completion of the sale, the insider now directly owns 206,400 shares in the company, valued at approximately $21,211,728. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 1,647 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $109.96, for a total value of $181,104.12. Following the sale, the insider now owns 114,186 shares of the company’s stock, valued at $12,555,892.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 84,308 shares of company stock worth $9,128,555. Company insiders own 7.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Canaccord Genuity Group boosted their price objective on shares of Natera from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Robert W. Baird boosted their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Jefferies Financial Group assumed coverage on shares of Natera in a research report on Monday, June 3rd. They set a “buy” rating and a $142.00 price objective for the company. TD Cowen boosted their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Stephens restated an “overweight” rating and set a $125.00 price objective on shares of Natera in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.07.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.